Roberto Palencia
Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Journal: Cancer reports (Hoboken, N.J.)
Published: November 01, 2022
Systematic literature review of current treatments for stage I-III Merkel cell carcinoma.
Journal: Future oncology (London, England)
Published: September 08, 2021
A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
Journal: Cancer reports (Hoboken, N.J.)
Published: December 07, 2020
A review of patient-reported outcome measures to assess female infertility-related quality of life.
Journal: Health and quality of life outcomes
Published: August 16, 2016
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: September 07, 2015
Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: January 04, 2015
Comparative Efficacy and Safety of Empagliflozin with Other Anti-Diabetic Drugs for the Treatment of Patients with Type 2 Diabetes Mellitus Who are Failing Insulin.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Cost-Effectiveness of Empagliflozin (Jardiance®) 10 Mg And 25 Mg Administered As An Add-On To Metformin And Sulfonilurea (Met+Su) Compared To Other Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2is) in Patients with Type 2 Diabetes Mellitus (T2dm) In The Uk.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Cost-Effectiveness of Empagliflozin (Jardiance®) 10 Mg And 25 Mg Administered As An Add-on To Metformin Compared To Other Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2is) for Patients With Type 2 Diabetes Mellitus (T2dm) In The UK.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Comparative Efficacy and Safety of Empagliflozin with Other Antidiabetic Drugs for the Third Line Treatment of Type 2 Diabetes Mellitus.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Comparative Efficacy and Safety of Empagliflozin with Other Oral Antidiabetic Drugs for the Second Line Treatment of Type 2 Diabetes Mellitus.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Development Of A Model To Assess The Cost-Effectiveness Of Therapies For Patients With Type 2 Diabetes Mellitus (T2DM) Following A Reference Model Framework.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Last Updated: 09/26/2026